Sign In
Buy LTRN
$3.40
-0.340 (-9.09%)
At Close: Jun 03, 2026
DALLAS--(BUSINESS WIRE)--ATRT data presented at SNO Pediatric 2025.
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
03:04pm, Thursday, 15'th May 2025
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Panna Sharma - President & CEO David Margrave - CFO Conference Call Participants Operat
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
08:45am, Thursday, 15'th May 2025
DALLAS--(BUSINESS WIRE)--Q1 2025 Lantern Pharma Earnings (LTRN).
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
08:30am, Thursday, 08'th May 2025
DALLAS--(BUSINESS WIRE)--Q1 Earnings Call Save The Date.
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
08:55am, Monday, 05'th May 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today
Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript
08:35pm, Thursday, 27'th Mar 2025
Lantern Pharma Inc. (NASDAQ:LTRN ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 AM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhat
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
04:01pm, Thursday, 27'th Mar 2025
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platfor
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
08:00am, Thursday, 20'th Mar 2025
DALLAS--(BUSINESS WIRE)--Q4 & Fiscal Year 2024 Earnings Call Save The Date.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence company transforming oncology drug development, and its wholly-owned subsidiary Starlight Therapeutics, focused
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript
07:23pm, Friday, 08'th Nov 2024
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bha
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
04:05pm, Thursday, 07'th Nov 2024
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and m
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
08:00am, Tuesday, 05'th Nov 2024
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation,
